VEGFA and renal cell carcinoma: in patients receiving VEGF tyrosine kinase inhibitors (VEGF-TKIs) successfully modulated the microbiota levels of this bacteria and led to some clinical benefit in the treatment group.120 In RCC patients receiving ICIs, greater gut microbiome diversity was associated with more positive treatment outcomes and heightened clinical benefit.121